Travere Therapeutics, Inc. (TVTX)
TVTX Stock Price Chart
Explore Travere Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze TVTX price movements and trends.
TVTX Company Profile
Discover essential business fundamentals and corporate details for Travere Therapeutics, Inc. (TVTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Nov 2012
Employees
385.00
Website
https://www.travere.comCEO
Eric Dube
Description
Travere Therapeutics, Inc., a biopharmaceutical firm headquartered in San Diego, California, was founded in 2008 with a mission to discover, develop, commercialize, and deliver treatments for rare diseases. The company adopted its current name in November 2020, previously operating as Retrophin, Inc. Its current product offerings include Chenodal, an orally administered synthetic form of chenodeoxycholic acid, used to dissolve radiolucent gallstones. Another key product is Cholbam, a cholic acid capsule prescribed for both children and adults suffering from bile acid synthesis disorders stemming from single enzyme defects, and as an auxiliary treatment for peroxisomal disorders. Additionally, Thiola and Thiola EC, tiopronin tablets, are available for managing homozygous cystinuria. In its development pipeline, Travere is advancing several therapeutic candidates. Sparsentan is currently in Phase III clinical trials, being investigated for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. Also under development is TVT-058, a pioneering investigational human enzyme replacement candidate, which is undergoing Phase I/II clinical trials for classical homocystinuria. The company actively engages in strategic partnerships, holding a cooperative research and development agreement with the National Institutes of Health's National Center for Advancing Translational Sciences. It also collaborates with patient advocacy groups such as CDG Care and the Alagille Syndrome Alliance, collectively working towards identifying potential small molecule therapies for NGLY1 deficiency and Alagille syndrome.
TVTX Financial Timeline
Browse a chronological timeline of Travere Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.08, while revenue estimate is $160.66m.
Earnings released on 4 May 2026
EPS came in at -$0.39 falling short of the estimated -$0.30 by -30.00%, while revenue for the quarter reached $127.20m , missing expectations by -6.63%.
Earnings released on 19 Feb 2026
EPS came in at $0.03 matching the estimated $0.03, while revenue for the quarter reached $129.69m , missing expectations by -10.28%.
Earnings released on 30 Oct 2025
EPS came in at $0.28 surpassing the estimated -$0.31 by +190.32%, while revenue for the quarter reached $164.86m , beating expectations by +12.16%.
Earnings released on 6 Aug 2025
EPS came in at -$0.14 surpassing the estimated -$0.28 by +50.00%, while revenue for the quarter reached $114.45m , beating expectations by +14.97%.
Earnings released on 1 May 2025
EPS came in at -$0.47 surpassing the estimated -$0.55 by +14.55%, while revenue for the quarter reached $81.73m , missing expectations by -7.96%.
Earnings released on 20 Feb 2025
EPS came in at -$0.73 falling short of the estimated -$0.58 by -25.86%, while revenue for the quarter reached $74.79m , beating expectations by +3.33%.
Earnings released on 31 Oct 2024
EPS came in at -$0.70 matching the estimated -$0.70, while revenue for the quarter reached $62.90m , missing expectations by -11.96%.
Earnings released on 1 Aug 2024
EPS came in at -$0.90 falling short of the estimated -$0.87 by -3.45%, while revenue for the quarter reached $54.12m , missing expectations by -6.33%.
Earnings released on 6 May 2024
EPS came in at -$1.76 falling short of the estimated -$0.98 by -79.59%, while revenue for the quarter reached $41.37m , missing expectations by -3.44%.
Earnings released on 15 Feb 2024
EPS came in at -$1.16 surpassing the estimated -$1.27 by +8.66%, while revenue for the quarter reached $45.06m , beating expectations by +8.55%.
Earnings released on 7 Nov 2023
EPS came in at -$1.17 falling short of the estimated -$1.09 by -7.34%, while revenue for the quarter reached $37.10m , missing expectations by -68.38%.
Earnings released on 3 Aug 2023
EPS came in at -$1.13 surpassing the estimated -$1.16 by +2.59%, while revenue for the quarter reached $59.70m , beating expectations by +11.15%.
Earnings released on 4 May 2023
EPS came in at -$1.27 falling short of the estimated -$1.18 by -7.63%, while revenue for the quarter reached $56.99m , beating expectations by +12.61%.
Earnings released on 23 Feb 2023
EPS came in at -$1.03 surpassing the estimated -$1.04 by +0.96%, while revenue for the quarter reached $55.87m , beating expectations by +5.38%.
Earnings released on 27 Oct 2022
EPS came in at -$1.09 falling short of the estimated -$0.97 by -12.37%, while revenue for the quarter reached $53.50m , missing expectations by -1.15%.
Earnings released on 4 Aug 2022
EPS came in at -$1.05 falling short of the estimated -$0.94 by -11.70%, while revenue for the quarter reached $54.17m , beating expectations by +9.14%.
Earnings released on 5 May 2022
EPS came in at -$1.20 falling short of the estimated -$0.85 by -41.18%, while revenue for the quarter reached $48.49m , missing expectations by -7.10%.
Earnings released on 24 Feb 2022
EPS came in at -$0.84 falling short of the estimated -$0.72 by -16.67%, while revenue for the quarter reached $57.25m , missing expectations by -0.95%.
Earnings released on 28 Oct 2021
EPS came in at -$0.59 surpassing the estimated -$0.72 by +18.06%, while revenue for the quarter reached $68.22m , beating expectations by +29.59%.
Earnings released on 29 Jul 2021
EPS came in at -$0.64 surpassing the estimated -$0.73 by +12.33%, while revenue for the quarter reached $54.62m , meeting expectations.
TVTX Stock Performance
Access detailed TVTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
